STAT+: The $10 billion question: Will Pfizer hit it big with Metsera, or have regrets?
At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's also taking on a lot of risk.
STAT+: Why a quarter of NC’s Medicaid members could lose coverage
This is the online version of STAT's weekly email newsletter Health Care Inc.
STAT+: Fate of ACA subsidies still clouded after deal to reopen the government
Democrats negotiated a future vote on Affordable Care Act tax credits in return for reopening the government, but there's no guarantee of passage.
FDA reverses decades-old warning on hormone therapy products for menopause
The FDA is reversing a 2003 decision that put a stringent warning on hormone therapy products for menopausal women, saying that the treatments offer heart, brain, and bone health benefits.
Canada loses measles elimination status — as does the entire Americas region
Canada has formally lost its measles elimination status, the country’s public health agency announced, triggering the loss of that status throughout all of the Americas.
STAT+: Medicaid’s ‘GENEROUS’ pricing may not save states money
Plus more biotech news stories, brought to you by The Readout
STAT+: Pharmalittle: We’re reading about a Merck cholesterol pill, the Trump deal for obesity drugs, and more
Merck pill designed to further lower cholesterol in people on statins but at risk of a serious cardiovascular event cut LDL cholesterol by up to 60%
Senate takes first step toward ending the government shutdown
The Senate took the first step to end the government shutdown on Sunday
STAT+: At AASLD, optimism about AI, Hep delta and Madrigal’s MASH drug
At the Liver Meeting, there was positive news about Rezdiffra for MASH and Vir's Hep delta candidate, along with hope on harnessing AI.
New research finds no link between Tylenol use during pregnancy and autism, despite Trump’s claims
And other health stories from the Morning Rounds newsletter